Artemis Investment Management LLP Buys 252,755 Shares of Repligen Corporation $RGEN

Key Points

• Artemis Investment Management increased its Repligen stake by 207.6%, buying 252,755 shares in the third quarter and bringing its holdings to 374,482 shares worth approximately $72 million.
• Analysts maintain a generally positive outlook, with Repligen carrying a consensus “Moderate Buy” rating and an average price target of $173.21; Barclays recently raised its target to $225.
• Repligen shares fell 3.8% to $160.88, while the company’s latest quarterly results exceeded expectations, reporting $0.54 in EPS and $204.13 million in revenue.

Artemis Investment Management LLP lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 207.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 374,482 shares of the biotechnology company's stock after purchasing an additional 252,755 shares during the period. Artemis Investment Management LLP owned about 0.66% of Repligen worth $71,987,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. United Capital Financial Advisors LLC acquired a new stake in Repligen in the 2nd quarter worth about $380,756,000. Maverick Capital Ltd. purchased a new position in shares of Repligen in the first quarter valued at approximately $178,946,000. Wasatch Advisors LP acquired a new stake in shares of Repligen in the first quarter worth approximately $146,513,000. William Blair Investment Management LLC purchased a new stake in shares of Repligen during the second quarter worth approximately $107,593,000. Finally, Bamco Inc. NY acquired a new position in Repligen in the 2nd quarter valued at $102,121,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. UBS Group reaffirmed a "buy" rating on shares of Repligen in a research note on Tuesday, September 29th. Zacks Research downgraded shares of Repligen from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. Barclays boosted their price target on shares of Repligen from $175.00 to $225.00 and gave the stock an "overweight" rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.21.

Repligen Trading Down 3.8%

NASDAQ:RGEN traded down $6.34 on Thursday, reaching $160.88. The company's stock had a trading volume of 491,567 shares, compared to its average volume of 1,042,244. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $198.87. The stock has a 50 day moving average price of $172.66 and a 200 day moving average price of $142.75. The firm has a market cap of $9.08 billion, a price-to-earnings ratio of 220.38, a price-to-earnings-growth ratio of 3.19 and a beta of 1.08. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same period in the prior year, the firm earned $0.26 earnings per share. The firm's revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company's portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.